[MDXG] MiMedx Group, Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.86 Change: 0.14 (1.61%)
Ext. hours: Change: 0 (0%)

chart MDXG

Refresh chart

Strongest Trends Summary For MDXG

MDXG is in the medium-term up 39% above S&P in 1 month. In the long-term down -77% below S&P in 2 years and up 435% in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: MiMedx Group, Inc., together with its subsidiaries, designs, manufactures, and markets products and tissue processing services in the United States. The company?s products include patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies comprise AmnioFix and EpiFix, which are tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through the company?s donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. It processes the human amniotic membrane utilizing its proprietary PURION process to produce a safe and effective implant. The company also provides CollaFix, a medical device technology platform. It supplies amniotic tissue on OEM basis for application in the wound care, surgical, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force,

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 59.41% Sales Growth - Q/Q3.02% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA10.58% ROE13% ROI
Current Ratio4.46 Quick Ratio4.23 Long Term Debt/Equity Debt Ratio0.21
Gross Margin89.36% Operating Margin8.78% Net Profit Margin8.05% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-13.96 M Cash From Investing Activities-1.17 M Cash From Operating Activities7.14 M Gross Profit40.59 M
Net Profit5.43 M Operating Profit5.65 M Total Assets113.84 M Total Current Assets91.81 M
Total Current Liabilities19.46 M Total Debt Total Liabilities20.6 M Total Revenue45.68 M
Technical Data
High 52 week8.96 Low 52 week1.15 Last close3.32 Last change-0.9%
RSI83.66 Average true range0.24 Beta0.39 Volume429.19 K
Simple moving average 20 days18.31% Simple moving average 50 days3.87% Simple moving average 200 days-7.83%
Performance Data
Performance Week9.55% Performance Month12.16% Performance Quart15.68% Performance Half32.27%
Performance Year-54.71% Performance Year-to-date85.47% Volatility daily5.1% Volatility weekly11.4%
Volatility monthly23.36% Volatility yearly80.91% Relative Volume207.6% Average Volume604.93 K
New High New Low

News

2019-06-17 11:25:00 | Shareholder Group Comments on MiMedx Shareholder Meeting

2019-06-17 09:39:00 | MiMedx Shareholders Overwhelmingly Support Election of All Three of MiMedx's Highly Qualified Director Nominees

2019-06-16 17:56:00 | MiMedx Continues to Fight against Holding 2019 Annual Meeting

2019-06-14 14:34:00 | Former Chairman and CEO _Pete_ Petit Highlights Flaws in Revenue Recognition Allegations

2019-06-14 09:00:00 | MiMedx Urges Shareholders to Vote Today _FOR_ All of the Board's Highly Qualified Nominees on the BLUE Proxy Card

2019-06-13 09:00:00 | MiMedx Highlights Skills and Experience of Director Nominees

2019-06-12 10:18:00 | Mimedx Shareholder Group Calls out Significant Drop in Mimedx’s Profitability since the Original CEO & COO Were Asked to Leave the Company on June 30th, 2018

2019-06-12 09:00:00 | Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending MiMedx Shareholders Vote _For_ All Three of the Company's Director Nominees

2019-06-11 16:30:00 | MiMedx Secures $75 million Non-Dilutive Debt Financing

2019-06-11 09:00:00 | Leading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That MiMedx Shareholders Vote the BLUE Card _FOR_ All Three of the Company's Director Nominees

2019-06-10 10:23:00 | Mimedx Shareholder Group Urges Shareholders to Vote on the White Proxy Card for the 2018 Annual Meeting of Mimedx Group, Inc. on June 17, 2019

2019-06-10 09:00:00 | MiMedx Issues Additional Information to Shareholders

2019-06-07 09:00:00 | MiMedx Urges Shareholders to Vote _FOR_ All of the Board's Qualified Nominees on the BLUE Proxy Card

2019-06-05 16:30:00 | MiMedx Issues New Presentation for Investors in Advance of 2018 Annual Meeting

2019-06-04 09:00:00 | MiMedx Shareholders Should Visit www.VoteBlueForMiMedx.com

2019-06-03 08:30:00 | MiMedx Files Definitive Proxy Materials and Mails Letter to Shareholders

2019-05-31 20:00:00 | Bed Bath & Beyond, Piece by Piece

2019-05-30 14:00:00 | Here's Why Shares of MiMedx Group Jumped Higher Today

2019-05-30 08:00:00 | MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

2019-05-28 16:27:00 | MiMedx Announces BDO as the Company's New Independent Registered Public Accounting Firm

2019-05-24 16:44:16 | MiMedx Internal Probe Finds Ex-CEO Secretly Videoed Workers

2019-05-24 12:23:46 | WSJ: MiMedx Injectables Flout FDA Regulations

2019-05-24 07:44:48 | The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

2019-05-23 17:19:00 | MiMedx probe finds execs spied on potential whistleblowers with secret video

2019-05-23 16:45:00 | MiMedx Announces Conclusion of Audit Committee's Independent Investigation

2019-05-10 21:42:00 | Activist Raging Capital Sizes Up Tidewater

2019-05-09 08:00:00 | MiMedx Appoints Timothy R. Wright as Chief Executive Officer

2019-05-09 04:00:02 | Georgia Senator Called VA, FDA, FBI on Behalf of MiMedx CEO

2019-05-07 11:55:00 | Prescience Point Nominates Slate of Highly-Qualified Director Candidates for Election to MiMedx Board

2019-04-29 19:55:59 | Penny Stocks to Watch for May 2019

2019-04-11 16:32:00 | MiMedx Announces Board Approval of Long-Range Strategic Plan

2019-02-22 14:28:00 | Short-Selling Is Really Hard. Just Ask Citron Research

2018-12-27 19:30:28 | [$$] Sen. Johnny Isakson Called FBI on Behalf of MiMedx Group

2018-12-12 07:00:00 | Today's Research Reports on Trending Tickers: MiMedx Group and Tandem Diabetes Care

2018-12-11 19:25:44 | [$$] MiMedx Called on Two Lawmakers for Help Before Its Accounting Scandal

2018-12-05 19:27:32 | [$$] MiMedx to Shed Jobs as Part of Overhaul

2018-12-05 10:12:51 | [$$] Help Wanted, Get in on Ground Floor

2018-12-05 08:05:00 | MiMedx Announces Resignation Of Outside Auditor

2018-12-05 08:02:00 | MiMedx Announces Leadership Changes And Promotions

2018-12-05 08:00:00 | MiMedx Announces Organizational Realignment Program

2018-11-20 09:05:00 | 4 Healthcare Stocks You Should Get To Know Before 2019

2018-11-08 07:05:00 | Today's Research Reports on Trending Tickers: Tandem Diabetes Care and MiMedx

2018-11-07 17:57:00 | Jack Henry & Associates Set to Join S&P 500; EQT, Equitrans Midstream, MasTec to Join S&P MidCap 400; Superior Energy Services, United Natural Foods to Join S&P SmallCap 600

2018-11-07 14:16:36 | [$$] Nasdaq to Delist MiMedx Amid Financial Probe

2018-11-07 13:08:00 | Here's Why MiMedx Group Shares Are Imploding 30% Today

2018-11-07 12:24:56 | MDXG News: MiMedx Stock Plunges on Nasdaq Delisting Notice

2018-11-07 09:55:00 | MiMedx stock plunges after receiving delisting notice from Nasdaq

2018-11-07 08:02:00 | MiMedx Adopts Limited Duration Shareholder Rights Plan In Response To Delisting From Nasdaq

2018-11-07 08:00:00 | MiMedx Receives Nasdaq Delisting Notification

2018-11-06 12:29:00 | MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference